Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Gefitinib Superior to Standard Chemotherapy in NSCLC Patients With EGFR Mutations NEW YORK -- December 21, 2009 -- Patients with non-small-cell lung cancer (NSCLC) who have mutations in the epidermal growth factor receptor (EGFR) gene have significantly improved progression-free survival (PFS) if they are treated with gefitinib compared with standard chemotherapy, according to a study published online first in The Lancet Oncology. Wherever possible, EGFR genetic testing must be done and gefitinib should be considered as the first-line treatment for patients with EGRF mutations, concluded the authors. Gefitinib has been shown to have considerable benefit in patients with NSCLC who are more likely to have EGFR mutations, such as those of Asian origin, women, and those who have never smoked. Recent trials of gefitinib monotherapy have failed to show any survival advantage in unselected patient populations. It has been suggested that this lack of survival advantage might be due to a lack of patient selection. To resolve this uncertainty, Tetsuya Mitsudomi, West Japan Oncology Group, and colleagues compared gefitinib with a standard chemotherapy regimen of cisplatin plus docetaxel in patients with NSCLC selected according to EGRF mutation status. A total of 177 patients with EGFR mutations were recruited from 36 centres in Japan and randomly assigned to receive either gefitinib (n = 88) or cisplatin plus docetaxel (n = 89) every 21 days for 3 to 6 cycles. Disease progression was regularly assessed using computed tomography and magnetic resonance imaging. Overall, patients in the gefitinib group had significantly longer PFS (9.2 months) compared with the chemotherapy group (6.3 months). In addition, findings showed that the objective response rate was significantly higher in the gefitinib group (62.1%) than in the cisplatin plus docetaxel group (32.2%). The disease control rate was also higher in the gefitinib group (93.1%) than in the chemotherapy group (78%). Gefitinib was also generally better tolerated than cisplatin plus docetaxel, and adverse events of grade 3 or more were infrequent and included skin rash, liver dysfunction, and diarrhoea. By contrast, the most common adverse events in the chemotherapy group occurred in more than half of patients and included nausea, myelosuppression, fatigue, and alopecia. “Our study indicates that EGFR genetic testing is feasible and should be done when possible…Considering the efficacy and toxicity of gefitinib, it is a reasonable option for the first-line treatment of patients with activating EGFR mutations,” the authors wrote. “These results strongly suggest that the presence of EGFR mutations, and not the clinical background of patients, determines clinical efficacy, and this knowledge should lead to molecularly based, personalised treatment of lung cancer in the near future.” SOURCE: The Lancet Oncology E-mail this page to a friend or colleague! To print, use this version